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Abstract
Machine learning (ML) applied to patient-reported (PROs) and clinical-assessed outcomes (CAOs) could favour a more predic-
tive and personalized medicine. Our aim was to confirm the important role of applying ML to PROs and CAOs of people with
relapsing-remitting (RR) and secondary progressive (SP) form of multiple sclerosis (MS), to promptly identifying information
useful to predict disease progression. For our analysis, a dataset of 3398 evaluations from 810 persons with MS (PwMS) was
adopted. Three steps were provided: course classification; extraction of the most relevant predictors at the next time point;
prediction if the patient will experience the transition from RR to SP at the next time point. The Current Course Assignment
(CCA) step correctly assigned the current MS course with an accuracy of about 86.0%. The MS course at the next time point can
be predicted using the predictors selected in CCA. PROs/CAOs Evolution Prediction (PEP) followed by Future Course
Assignment (FCA) was able to foresee the course at the next time point with an accuracy of 82.6%. Our results suggest that
PROs and CAOs could help the clinician decision-making in their practice.
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Introduction
Following the major revolution that is undergoing in medi-
cine, the nature of healthcare is shifting from a disease centred
to a patient-centred approach [1]. Beside emerging medical
disciplines, such as genomic medicine, recently, participatory
medicine is gaining increasing attention for diagnostic or ther-
apeutic decision-making, consequently requiring new insights
in patient involvement. Also, for multiple sclerosis (MS), in-
novative strategies to use traditional clinical measurements
(i.e. patient-reported outcomes (PROs), clinician-assessed
outcomes (CAOs)) and new computational tools (e.g. ma-
chine learning (ML)) could favour the shift from the current
reactive medicine mode towards a personalized, predictive,
preventive and participatory medicine [2]. In particular, the
application of ML to PROs and CAOs could become the key-
stone [3] to better detect the rapid changes due to the pathol-
ogy evolution and, consequently, to pave a timelier, low-cost
and patient-centred way for people withMS (PwMS) manage-
ment. Although, ML approaches [4] have proven to be able to
extract meaningful information hidden in the data in a wide
range of biomedical applications [5, 6], their role in analyzing
PROs and CAOs of PwMS has still to be fully consolidated
[7]. Several instrumental measures (e.g. MRI) offer
established and well-known biomarkers of disease activity,
especially for relapsing-remitting (RR) course of MS; those
are currently less useful in detecting the transition from RR to
the secondary progressive (SP) form [8]. Thus, ML applied to
PROs and CAOs could be valuable to fill this gap or to im-
prove MRI prediction power. Here, we applied previously
developed machine learning algorithms [7] to a dataset
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(PROMOPRO-MS database) populated of PROs and CAOs
exclusively from RR and SP PwMS, by confirming the deci-
sive role that ML approaches could play in the future in timely
identifying information useful to predict the progression from
RR to SP course and consequently in supporting pharmaco-
logical and rehabilitative therapeutic decision-making in order
to prevent this transition.
Materials and methods
Patients followed as outpatients or at-home by ItalianMultiple
Sclerosis Society (AISM) Rehabilitation Centres of Genoa,
Padua and Vicenza, have been progressively enrolled in the
study [9] without any inclusion/exclusion criteria unless MS
diagnosis. The study was approved by the local ethics com-
mittee (Comitato Etico Aziendale A.O. Universitaria BSan
Martino^ Genova). A written informed consent was obtained
from all subjects prior to study entry.
Personal (i.e. years of education), clinical (i.e. number of
relapses in the last 4 months) and biometric (i.e. height and
weight) data, PROs and CAOs related to the most relevant
domains for MS (i.e. mobility, fatigue, cognitive perfor-
mances, emotional status, bladder continence, quality of life),
were acquired each 4 months from January–May 2014 to
May–September 2017 for a maximum of 11 evaluations for
Table 1 Personal, clinical, biometric, clinician assessed outcome (CAO) and patient reported outcomes (CAO) data acquired 4 months each from
January-May 2014 to May-September 2017
Predictors contained in the vectors of the dataset
Code Data type No. of items No. of subtotal scores No. of total scores
ABILHAND ABILH PRO 23 - 1
Edinburgh Handedness Inventory EHI PRO 10 - 1
Hospital Anxiety and Depression Scale HADS PRO 14 2 1
Life Satisfaction Index LSI PRO 11 - 1
Modified Fatigue Impact Scale MFIS PRO 21 3 1
Overactive Bladder Questionnaire OAB-q PRO 8 - 1
Functional Independence Measure FIM CAO 19 6 1
Montreal Cognitive Assessment MoCA CAO 11 - 2
Paced Auditory Serial Addition Task PASAT CAO - - 1
Symbol Digit Modalities Test SDMT CAO - - 1
Education (years) EDU Personal - - 1
Relapses in the last 4 months (no.) RELAPS Clinical - - 1
Height (cm) H Biometric - - 1
Weight (kg) W Biometric - - 1
Predictors selected in disease course classification and prediction
ABILH (item 12) Hammering a nail
ABILH (TOT) ABILH total score
HADS (item 7) I can sit at ease and feel relaxed.
HADS (SUB1) HADS subtotal measuring anxiety
HADS (SUB2) HADS subtotal measuring depression
HADS (TOT) HADS total score
LSI (TOT) LSI total score
MFIS (item 2) I have had difficulty paying attention for long periods of time.
MFIS (SUB1) MFIS subtotal measuring cognitive status
MFIS (SUB2) MFIS subtotal measuring physical status
MFIS (SUB3) MFIS subtotal measuring psychosocial status
MFIS (TOT) MFIS total score
OAB-q (item 1) Frequent urination during the daytime hours
OAB-q (item 4) Accidental loss of small amounts of urine
OAB-q (TOT) OAB-q total score
FIM (item 10) How much assistance is required for toilet transfer?
FIM (item 11) How much assistance is required for shower transfer?
FIM (item 12) How much assistance is required for locomotion (ambulatory)?
FIM (item 14) How much assistance is required for locomotion (wheelchair)?
FIM (SUB3) FIM subtotal measuring sphincter control
FIM (SUB4) FIM subtotal measuring personal care
FIM (SUB5) FIM subtotal measuring locomotion
FIM (SUB6) FIM subtotal measuring mobility
FIM (TOT) FIM total score
MoCA (item 1) Visuoconstructional test
MoCA (item 9) Memory test
MoCA (TOT1) MOCA total score
MoCA (TOT2) MOCA total score corrected for year of education
PASAT Score
SDMT Score
EDU Years of formal education
H Height (cm)
W Weight (kg)
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each participant. Each sample of the dataset is represented by a
vector containing 143 predictors (i.e. single question, subtotal
scores and total scores) (Table 1) and adopted to finally refine
previously developed ML algorithms [7].
We proceeded through a three-step strategy based on su-
pervised ML algorithms in order to develop a MS evolution
temporal model (i.e. from RR to SP): Current Course
Assignment (CCA), PROs/CAOs Evolution Prediction
(PEP) and Future Course Assignment (FCA). In particular,
CCA solves a binary classification problem: each predictor
vector, independently of evaluations time course, is associated
with the most probable MS form (RR or SP). PEP provides an
updated historical representation: for each patient, the most
probable predictor vector at the next time point is predicted.
FCA model is just the function composition of FCA and PEP.
Therefore, it allows foreseeing if the patient at the next time
point will be RR or SP, by allowing inferring if he/she will
experience the transition.
Results
A total of 3398 evaluations from 810 PwMS represented the
dataset adopted for our analysis. Among those, 1451 were RR
PwMS at the evaluation time and 1947 SP PwMS. The CCA
step correctly assigned the current MS course with an accura-
cy of about 86.0%. This was obtained through a reduced num-
ber of predictors from the considered PROs and CAOs and
from biometric and personal data (Table 1). Specifically, self-
and physician-reported information of the physical domain
(upper limb abilities, fatigue, personal care and locomotion)
and few self-reported information of present and past mood
and quality of life, as well as clinically assessed performances
in cognitive tests (memory, calculation, information process-
ing), were necessary.
Although important, the most interesting result was obtain-
ed from the second and third steps of the analysis. By using
the predictors selected in CCA, PEP followed by FCA was
able to foresee the course at the next time point with an accu-
racy of 82.6%.
The results suggest that the disease course prediction based
on PROs and CAOs is feasible in MS. However, although a
reduced number of predictors is selected with respect to those
originally considered, disease course prediction at the next
time point requires to acquire all 143 predictors.
Conclusion
Here, we presented a data analysis pipeline based on ML
methods that could address MS diagnosis and prognosis is-
sues. Our results show that PROs and CAOs could be used to
build accurate models of MS disease course prediction. PROs
and CAOs, alone or integratedwith other indexes such asMRI
outcomes and biomarkers, could help the decision-making
process of clinicians in their daily practice. The main limita-
tion of the current prediction algorithm is the considerable
amount of data needed. Future developments of the algorithm
that will integrate also data on therapies followed by the pa-
tients already present in the current database and eventually
MRI outcomes will take into account the necessity to optimize
andminimize the necessary data. In conclusion, the possibility
to better define the clinical complexity levels of the patient and
to have sufficient and adequate predictive criteria for MS evo-
lution could be an instrument for the construction of a more
fruitful therapeutic pact between clinician and patient based
on better perspective knowledge, increased disease conscious-
ness and engagement in pharmacological and rehabilitative
treatments, and physical activity, to date, is considered the
main way to delay MS progression and to improve quality
of life [10].
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